Drugs / CD68-ET3
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04418414 | Sep 2024 → Aug 2029 expected | hemophilia A | Expression Therapeutics, LLC | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD68-ET3 | “CD34+ hematopoietic stem cells transduced with CD68-ET3 lentiviral vector (encoding human factor VIII gene) is administered by IV infusion following conditioning regimen with...” NCT04418414 ↗ |
| Route | Intravenous | “administered by IV infusion” NCT04418414 ↗ |
| Target | F8 | “encoding human factor VIII gene” NCT04418414 ↗ |